96 related articles for article (PubMed ID: 14728804)
41. CD81 binding regions of hepatitis C virus remain conserved after liver transplantation.
Lyra AC; Fan X; Di Bisceglie AM
Braz J Infect Dis; 2004 Apr; 8(2):126-32. PubMed ID: 15361990
[TBL] [Abstract][Full Text] [Related]
42. DNA-based selection and screening of peptide ligands.
Bartoli F; Nuzzo M; Urbanelli L; Bellintani F; Prezzi C; Cortese R; Monaci P
Nat Biotechnol; 1998 Nov; 16(11):1068-73. PubMed ID: 9831038
[TBL] [Abstract][Full Text] [Related]
43. [Determination of glycyrrhizic acid binding sites by a phage display method].
Il'ina TV; Fediuk NV; Bachinskiĭ AG; Tumanova OIu; Kuvshinov VN; Il'ichev AA; Pokrovskiĭ AG
Mol Biol (Mosk); 2003; 37(5):861-7. PubMed ID: 14593923
[TBL] [Abstract][Full Text] [Related]
44. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes.
Henry SD; van der Wegen P; Metselaar HJ; Tilanus HW; Scholte BJ; van der Laan LJ
Mol Ther; 2006 Oct; 14(4):485-93. PubMed ID: 16872906
[TBL] [Abstract][Full Text] [Related]
45. [Identification of HCV antigen epitopes from a random 15-peptide library by anti-HCV polycloral antibody].
Ke S; Zhu JP; Wen XY; Zhao P; Shi M; He YH; Yao ZJ; Shen BF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):65-7. PubMed ID: 15132911
[TBL] [Abstract][Full Text] [Related]
46. Cellular receptors and HCV entry.
Flint M; Tscherne DM
Methods Mol Biol; 2009; 510():265-77. PubMed ID: 19009268
[TBL] [Abstract][Full Text] [Related]
47. Selection of CC chemokine receptor 5-binding peptide from a phage display peptide library.
Wang FY; Zhang TY; Luo JX; He GA; Gu QL; Xiao F
Biosci Biotechnol Biochem; 2006 Sep; 70(9):2035-41. PubMed ID: 16960395
[TBL] [Abstract][Full Text] [Related]
48. Identification and immunogenicity of an immunodominant mimotope of Avibacterium paragallinarum from a phage display peptide library.
Wang H; Gao Y; Gong Y; Chen X; Liu C; Zhou X; Blackall PJ; Zhang P; Yang H
Vet Microbiol; 2007 Jan; 119(2-4):231-9. PubMed ID: 17049758
[TBL] [Abstract][Full Text] [Related]
49. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
50. A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody.
Hardy B; Raiter A
Vaccine; 2005 Jul; 23(34):4283-91. PubMed ID: 15919139
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
[TBL] [Abstract][Full Text] [Related]
52. Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C.
Prinz DM; Smithson SL; Westerink MA
J Immunol Methods; 2004 Feb; 285(1):1-14. PubMed ID: 14871530
[TBL] [Abstract][Full Text] [Related]
53. [Adenovirus mediated expression of interleukin 12 regulating hepatitis C virus E2 gene immunization-induced immune response].
Wu CD; Li HG; Tao QM; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):620-2. PubMed ID: 15504296
[TBL] [Abstract][Full Text] [Related]
54. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.
Flint M; Maidens C; Loomis-Price LD; Shotton C; Dubuisson J; Monk P; Higginbottom A; Levy S; McKeating JA
J Virol; 1999 Aug; 73(8):6235-44. PubMed ID: 10400713
[TBL] [Abstract][Full Text] [Related]
55. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor.
Masciopinto F; Campagnoli S; Abrignani S; Uematsu Y; Pileri P
Virus Res; 2001 Nov; 80(1-2):1-10. PubMed ID: 11597743
[TBL] [Abstract][Full Text] [Related]
56. Structural characterization of peptide fragments from hCD81-LEL.
Dhanasekaran M; Baures PW; VanCompernolle S; Todd S; Prakash O
J Pept Res; 2003 Feb; 61(2):80-9. PubMed ID: 12492902
[TBL] [Abstract][Full Text] [Related]
57. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines.
Hamaia S; Li C; Allain JP
Blood; 2001 Oct; 98(8):2293-300. PubMed ID: 11588022
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis C virus infection of mouse hepatoma cell expressing human CD81 or LDLR.
Lv LP; Jia SZ; Wang QL; Zhang YY; Zhou H; Xu JB
Acta Virol; 2009; 53(3):185-9. PubMed ID: 19941400
[TBL] [Abstract][Full Text] [Related]
59. A Conserved Domain of HCV E2 Glycoprotein Interacts with Human CD81 and Induces Interferon-Gamma Secretion from Peripheral Blood Mononuclear Cells.
Dai Z; Zeng W; Li G; Shu X
Front Biosci (Landmark Ed); 2023 Oct; 28(10):239. PubMed ID: 37919063
[TBL] [Abstract][Full Text] [Related]
60. Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.
Chen F; Zhao Y; Liu M; Li D; Wu H; Chen H; Zhu Y; Luo F; Zhong J; Zhou Y; Qi Z; Zhang XL
Antimicrob Agents Chemother; 2010 Aug; 54(8):3355-64. PubMed ID: 20479194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
